CTLA4 and plasma cell myeloma: Immune checkpoint blockade was evaluated in this setting supported by pre-clinical studies which showed overexpression of PDL-1 in myeloma cells and CTLA4+ regulatory T cells in the tumor microenvironment.PDL-1 expression has also been shown to increase the risk of progression from monoclonal gammopathy to multiple myeloma (79–81).